Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAMK2D | Q13557 | 3/20 | 0.82 |
| ▸ | ABL1 | P00519 | 6/20 | 0.80 |
| ▸ | BCR | P11274 | 5/20 | 0.80 |
| ▸ | SRC | P12931 | 2/20 | 0.80 |
| ▸ | EGFR | P00533 | 2/20 | 0.80 |
| ▸ | PRKACA | P17612 | 1/20 | 0.80 |
| ▸ | PRKACG | P22612 | 1/20 | 0.80 |
| ▸ | PRKACB | P22694 | 1/20 | 0.80 |
| ▸ | PLK1 | P53350 | 3/20 | 0.76 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.70 |
| ▸ | MEN1 | O00255 | 1/20 | 0.70 |
| ▸ | NPC1 | O15118 | 1/20 | 0.70 |
| ▸ | RAB9A | P51151 | 1/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.70 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.70 |
| ▸ | JAK2 | O60674 | 1/20 | 0.63 |
| ▸ | SYK | P43405 | 1/20 | 0.62 |
| ▸ | CDK4 | P11802 | 1/20 | 0.62 |
| ▸ | CDK2 | P24941 | 1/20 | 0.62 |
| ▸ | PRKCA | P17252 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27444270 | 0.93 | PLK1 (0.78) | CAMK2DABL1BCRSRCEGFR | |
| SCHEMBL4386919 | 0.93 | ABL1 (0.82) | CAMK2DABL1BCRSRCEGFR | |
| SCHEMBL5471964 | 0.91 | ABL1 (0.71) | CAMK2DABL1BCRSRCEGFR | |
| SCHEMBL14530851 | 0.91 | PLK1 (0.75) | CAMK2DABL1BCRSRCEGFR | |
| SCHEMBL2945644 | 0.91 | PLK1 (0.79) | CAMK2DABL1BCRSRCEGFR | |
| SCHEMBL12801709 | 0.91 | CAMK2D (1.00) | CAMK2DABL1BCRSRCEGFR | |
| SCHEMBL12801287 | 0.90 | PLK1 (0.82) | CAMK2DABL1BCRSRCEGFR | |
| SCHEMBL2944432 | 0.90 | ABL1 (0.82) | CAMK2DABL1BCRSRCEGFR | |
| SCHEMBL1465 | 0.89 | ABL1 (1.00) | CAMK2DABL1BCRSRCEGFR | |
| SCHEMBL1789 | 0.89 | ABL1 (1.00) | CAMK2DABL1BCRSRCEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080153822-A1 | Methods of treating pain | INGENIUM PHARMACEUTICALS GMBH (DE) | 2008-06-26 | — | — | US | claimed |
| US-20070021419-A1 | 2-Aminophenyl-4-phenylpyrimidines as kinase inhibitors | CYCLACEL LIMITED (GB) | 2007-01-25 | — | — | US | claimed |
| US-9133214-B2 | Heteroalkyl linked pyrimidine derivatives | S*BIO PTE LTD (SG) | 2015-09-15 | — | — | US | disclosed |
| US-9133214-B2 | Heteroalkyl linked pyrimidine derivatives | S*BIO PTE LTD (SG) | 2015-09-15 | — | — | US | disclosed |
| US-9133214-B2 | Heteroalkyl linked pyrimidine derivatives | S*BIO PTE LTD (SG) | 2015-09-15 | — | — | US | disclosed |
| US-20120142680-A1 | HETEROALKYL LINKED PYRIMIDINE DERIVATIVES | S*BIO PTE LTD. (SG) | 2012-06-07 | — | — | US | disclosed |
| US-20120142680-A1 | HETEROALKYL LINKED PYRIMIDINE DERIVATIVES | S*BIO PTE LTD. (SG) | 2012-06-07 | — | — | US | disclosed |
| US-20120142680-A1 | HETEROALKYL LINKED PYRIMIDINE DERIVATIVES | S*BIO PTE LTD. (SG) | 2012-06-07 | — | — | US | disclosed |
| US-8143255-B2 | Heteroalkyl linked pyrimidine derivatives | S*BIO PTE LTD. (SG) | 2012-03-27 | — | — | US | disclosed |
| US-8143255-B2 | Heteroalkyl linked pyrimidine derivatives | S*BIO PTE LTD. (SG) | 2012-03-27 | — | — | US | disclosed |
| US-8143255-B2 | Heteroalkyl linked pyrimidine derivatives | S*BIO PTE LTD. (SG) | 2012-03-27 | — | — | US | disclosed |
| US-20070021419-A1 | 2-Aminophenyl-4-phenylpyrimidines as kinase inhibitors | CYCLACEL LIMITED (GB) | 2007-01-25 | — | — | US | disclosed |
| US-20070021419-A1 | 2-Aminophenyl-4-phenylpyrimidines as kinase inhibitors | CYCLACEL LIMITED (GB) | 2007-01-25 | — | — | US | disclosed |
| US-20070021419-A1 | 2-Aminophenyl-4-phenylpyrimidines as kinase inhibitors | CYCLACEL LIMITED (GB) | 2007-01-25 | — | — | US | disclosed |
| EP-1648875-A1 | 2-AMINOPHENYL-4-PHENYLPYRIMIDINES AS KINASE INHIBITORS | Cyclacel Limited (GB) | 2006-04-26 | — | — | EP | disclosed |
| EP-1562911-A1 | COMPOSITIONS USEFUL AS INHIBITORS OF JAK AND OTHER PROTEIN KINASES | Vertex Pharmaceuticals Incorporated (US) | 2005-08-17 | — | — | EP | disclosed |
| WO-2005012262-A1 | 2-AMINOPHENYL-4-PHENYLPYRIMIDINES AS KINASE INHIBITORS | CYCLACEL LIMITED (GB) | 2005-02-10 | — | — | WO | disclosed |
| WO-2005012262-A1 | 2-AMINOPHENYL-4-PHENYLPYRIMIDINES AS KINASE INHIBITORS | CYCLACEL LIMITED (GB) | 2005-02-10 | — | — | WO | disclosed |
| US-20040147507-A1 | Compositions useful as inhibitors of JAK and other protein kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2004-07-29 | — | — | US | disclosed |
| WO-2004041789-A1 | COMPOSITIONS USEFUL AS INHIBITORS OF JAK AND OTHER PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2004-05-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021419-A1 | 2-Aminophenyl-4-phenylpyrimidines as kinase inhibitors | GRK3, NCOR1, GRM3 | CAMK2D 1264/4885ABL1 684/4885BCR 1561/4885 |
| US-20120142680-A1 | HETEROALKYL LINKED PYRIMIDINE DERIVATIVES | TK1, TK2, DPYD | CAMK2D 1819/4885ABL1 252/4885BCR 798/4885 |
| US-20080153822-A1 | Methods of treating pain | OPRL1, ACHE, OPRK1 | CAMK2D 1498/4885ABL1 1154/4885BCR 4679/4885 |
| US-20040147507-A1 | Compositions useful as inhibitors of JAK and other protein kinases | JAK1, JAK2, JAK3 | CAMK2D 442/4885ABL1 6/4885BCR 864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.